首页LCTX • NYSEAMERICAN
Lineage Cell Therapeutics Inc
$0.58
盘前:
$0.55
(5.24%)-0.030
已休市: 1月13日, GMT-5 04:33:35 · USD · NYSEAMERICAN · 免责声明
股票在美国上市的证券
昨日收盘价
$0.53
当日价格范围
$0.51 - $0.58
年度波幅
$0.48 - $1.61
市值
1.28亿 USD
平均交易量
317.33万
市盈率
-
股息率
-
财务信息
损益表
收入
净收入
(USD)2024年9月年同比变化
收入
377.90万203.29%
经营支出
441.00万9.13%
净收入
-303.40万57.33%
净利润率
-80.2985.93%
每股收益
-0.0250.37%
息税折旧摊销前利润
-369.90万43.35%
有效税率
总资产
负债总额
(USD)2024年9月年同比变化
现金及短期投资
3271.10万-20.86%
总资产
9659.40万-9.00%
负债总额
3180.00万-19.48%
权益总额
6479.40万
发行在外的股份
1.89亿
市净率
1.52
资产回报率
-9.63%
资本回报率
-13.98%
现金净变动
(USD)2024年9月年同比变化
净收入
-303.40万57.33%
来自运营的现金
-578.70万-14.89%
投资现金
388.80万83.22%
融资现金
-3000.00-100.37%
现金净变动
-186.40万23.86%
自由现金流
-227.00万12.27%
简介
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Wikipedia
成立时间
1990
员工数量
72
搜索
清除搜索内容
关闭搜索框
Google 应用
主菜单